✦ LIBER ✦

PCR-SSCP fingerprinting of E2 of HCV in patients treated with interferon-α: A simple method for the assessment of genomic changes

Book ID: 118566826
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 120 KB
Volume: 21
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)81022-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Steatosis is the predictor of relapse in

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR

✍ L. Restivo; R. Zampino; B. Guerrera; L. Ruggiero; L. E. Adinolfi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Usefulness of simple assays for serum co

Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy

✍ Toshio Suzuki; Eiji Tanaka; Akihiro Matsumoto; Akihiko Urushihara; Takeshi Sodey 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

## Abstract The use of two new assays was evaluated for predicting the response to interferon (IFN) therapy in patients with chronic hepatitis C. The genotype of hepatitis C virus (HCV) was establishe by an enzyme‐linked immunosorbent assay based on genotype‐specific recombinant peptides of the NS4

630 Baseline factors associated with hae

630 Baseline factors associated with haematological toxicity of pegylated interferon α-2a and ribavirin for the treatment of HCV infection in HIV coinfected patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 250 KB

[589] SVR RATES ARE IMPACTED BY RVR/EVR

[589] SVR RATES ARE IMPACTED BY RVR/EVR AND FIBROSIS SCORE IN PATIENTS TREATED WITH TARIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2a FOR THE TREATMENT OF HCV

✍ S. Flamm; M. Rodriguez-Torres; M. Silva; Y. Li; B. Murphy 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Emergence of occult minority genotype 2b

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

✍ A.J. Buckton; R. Kulasegaram; S.L. Ngui; M. Fisher; R. James; S. Rangarajan; C.G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 362 KB

Final analysis of the ECOG I-COPA trial

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma treated with interferon alfa (IFN-α2a) plus an anthracycline-based induction regimen

✍ Smalley, R V; Weller, E; Hawkins, M J; Oken, M M; O’Connell, M J; Haase-Statz, S 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 112 KB